J&J makes new investments in microbiome R&D; UK’s Arix out to raise £100 million for new biotech investments
• J&J is making some new investments in microbiome research, including adding Caelus Health to its J&J Innovation portfolio. “These collaborations and investments will create critical new insights to address metabolic disorders through microbiome-based diagnostics and therapeutics,” said Dirk Gevers, PhD, Global Head, Janssen Human Microbiome Institute. “By partnering with entrepreneurs, biotechs and academics and bringing innovative opportunities together with our expertise, we look to move microbiome science forward and deliver future solutions that promote individual health.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.